The N.Y. Times just published an article about living with Stage 4 metastatic cancer. I’m interested in this because I’m a bilateral breast cancer survivor myself. By dint of research, mammograms and a rapid MRI which I paid for out of pocket, the cancers were caught at Stage 1 (< 1 cm). Having a multigenerational history of BC and a suspicious MRI, I got bilateral mastectomy in 2015. There’s a chance that it will return years later. No way to know.
This article is a tear-jerker but lacks financial information.
https://www.nytimes.com/2026/06/12/well/cancer-stage-4-terminal.html
..
Kate has Stage 4 breast cancer. Or, more specifically, Kate is currently living with and dying from Stage 4 breast cancer. That’s the truest way to put it, she says: It’s been almost four years since her diagnosis, so the disease almost resembles a chronic illness — except the specter of death hovers much nearer… [end quote]
A tremendous amount of money and effort has been poured into the search for chemotherapies for Stage 4 BC, with considerable success.
I remember TMF’s trenchrat saying that his cancer treatment caused money to melt away like ice cream on a Florida sidewalk.
What is the size of the market for drugs used to treat Stage 4 cancer?
The global market specifically for metastatic (Stage 4) cancer treatments is valued at $96.53 billion. Driven by an increase in advanced-stage diagnoses and the rapid rollout of expensive new therapies, this targeted market is projected to expand at a compound annual growth rate (CAGR) of 7.3%, reaching $158.08 billion.
Targeted therapies (like monoclonal antibodies) and immunotherapies (like checkpoint inhibitors) are driving the vast majority of the revenue growth.
The financial scale of this market is intensely concentrated around skyrocketing per-patient drug costs. Modern advanced-stage treatments—such as custom immunotherapies, antibody-drug conjugates (ADCs), or specialized targeted inhibitors—frequently launch at price tags exceeding $100,000 to $200,000 per year of treatment, with single-dose or short-course treatments sometimes crossing the $300,000 mark.
When a patient receives an intravenous (IV) chemotherapy, a targeted monoclonal antibody, or an immunotherapy infusion at an independent oncology clinic or a hospital outpatient department, it is billed as a medical procedure under the Medical Benefit. This falls strictly under Medicare Part B (Outpatient Medical Insurance).
The rise of “precision medicine” has led to a massive wave of oral oncology drugs—such as tyrosine kinase inhibitors (TKIs) taken as a daily pill at home. These are handled entirely differently, bypassing the clinic’s inventory entirely. They are routed through the Pharmacy Benefit. This falls under Medicare Part D (Prescription Drug Plans). Maximum out-of-pocket prescription drug costs under Medicare Part D are capped at $2,000 per year, dramatically shifting the remaining financial burden onto the Part D insurance plans and the government. [end Gemini quote]
This cap is fairly recent. The ruinous cost of chemo drugs is no longer the determinant of who is able to afford them.
Treating metastatic cancer is now like treating many other potentially deadly chronic diseases. It’s still a death sentence but the remaining life could be years…if the specific mutation can be treated by one of the targeted drugs.
The Macro cost is high. But that was probably recognized decades ago when President Richard Nixon declared a war on cancer.
The beneficiaries are the patients, the drug marketers, the middlemen and the doctors who administer the drugs. There’s some push-back but ultimately the people who choose to use the drugs are not paying the price. So there’s plenty of incentive for developing new drugs.
Wendy